Human parvovirus B19 infection and antiphospholipid antibodies
Introduction
Parvovirus B19 was discovered in 1975 as a cause of systemic infections of adults who either were asymptomatic or had mild nonspecific symptoms such as headache, pyrexia, malaise, fatigue, and myalgia [1]. In 1983, parvovirus B19 was identified as the etiological agent of erythema infectiosum, also known as fifth disease [2]. The virus occurs worldwide but is restricted exclusively to human hosts. The manifestations of parvovirus B19 infection may vary with the immunologic and haematologic status of the host. In healthy individuals, parvovirus B19 infection may cause a self-limiting subclinical erythroid aplasia, that is followed by a rash or arthralgia [3]. In patients suffering from diminished production or increased destruction of erythoid cells parvovirus B19 infection can result in a dramatic decrease of haemoglobin leading to aplastic crisis [4]. After the infection and immunological elimination from the peripheral blood, viral genomes have been shown to be present in cells of bone marrow and skin, in synovial cells, in tissues from liver and in the endothelium of the myocardium [5]. Persistent parvovirus B19 infection can occur in both immunocompetent and in immunodeficient individuals and may be associated with chronic anemia and/or a variety of other symptoms, for example, myo- and pericarditis, hepatitis and autoimmune phenomena.
Section snippets
Biology of parvovirus B19
The virion is a small non-enveloped particle with an average diameter of 22 to 24 nm (Fig. 1) containing a single-stranded DNA-genome of 5.596 nucleotides in length [6]. The infectious particles may contain either positive or negative strands of DNA. The icosahedral capsid consists of two structural proteins, VP1 (83 kDa) and VP2 (58 kDa), which are identical except for 227 amino acids at the amino-terminal of the VP1-protein, the so-called VP1-unique region. Each capsid consists of a total of
Epidemiology
Parvovirus B19 occurs worldwide but restricted exclusively to human hosts. The majority of infections occur during childhood and adolescence. Seroprevalence (specific IgG against the capsid proteins) is approximately 2–15% in children at an age of 1 to 5 years, 30–40% in adolescents (15 years of age) and 40–60% in young adults (20 years of age) [8]. The prevalence of IgG-antibodies reaches maximal levels in the elderly in which more than 90% are positive. Although the infection is endemic,
Immune response
During the course of parvovirus B19 infection infected individuals develop specific humoral immune responses against the viral proteins (Fig. 3A). Viraemia has its onset 6 days after infection with levels up to 1013 virus particles per milliliter blood and declines a few days later, mostly in combination with the appearance of IgM antibodies. The initial IgM antibody response is almost entirely directed against linear and conformational epitopes in the VP2-proteins. VP1-specific IgM-antibodies
Non-autoimmune manifestations of parvovirus B19 infection
In common parvovirus B19 infection is without any clinical symptoms or may result in a flu like disease. Particularly children may suffer from erythema infectiosum, a self-limiting rash illness [15], [16]. Parvovirus B19 has been further associated with a wide spectrum of diseases (Table 1): transient anemia, leucocytopenia or thrombocytopenia may occur without requiring any therapy. However, in some patients severe thrombocytopenia, pure red cell aplasia or pancytopenia were observed [17].
Parvovirus B19 infection and autoimmune aspects
Beside these commonly occurring symptoms parvovirus B19 has been correlated with a variety of different autoimmune diseases that are summarized in Table 2. Soon after the discovery of parvovirus B19 as the infectious agent causing erythema infectiosum an association between acute infection and arthalgia was reported. Arthralgias and arthritis are commonly reported in association with parvovirus B19 infection in adults whereas erythema infectiosum is the main symptom observed in children [21].
Pathogenesis
The pathogenesis of B19 infection begins with acquisition of virus usually via the respiratory tract, following which replication is presumed to occur in the nasopharyngeal lymphoid tissue leading to viraemia on day 6 [3] with subsequent infection and destruction of erythroblasts in the bone marrow. Various studies document a direct pathogenic or ‘lytic’ effect on erythroid cell precursors, and the giant pronormoblast (25–32 μm diameter), also referred to as the lantern cell, is characteristic,
References (36)
- et al.
Parvovirus-like particles in human sera
Lancet
(1975) - et al.
The human parvovirus, the cause of erythema infectiosum (fifth disease)?
Lancet
(1983) - et al.
Most of the VP1-unique region of parvovirus B19 is on the capsid surface
Virology
(1995) - et al.
Chronic human parvovirus B19 infection in rheumatic diseases of childhood and adolescence
J Clin Virol
(2002) Parvovirus infections in children and adults
Adv Pediatr
(1999)- et al.
Human parvovirus B19 infection associated with acute meningoencephalitis
Lancet
(2001) - et al.
Transient anticardiolipin antibody syndrome in a patient with parvovirus B19 infection
Am J Med
(2000) - et al.
Experimental parvoviral infection in humans
J Infect Dis
(1985) - et al.
Occurrence of infection with a parvovirus-like agent in children with sickle cell anaemia during a two-year period
J Clin Pathol
(1982) - et al.
Parvovirus B19: a pathogen responsible for more than hematologic disorders
Virchows Arch
(2003)